Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENA-6
2021-000546-17Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-000546-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000546-17.